Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Corvus Pharmaceuticals (CRVS) Income from Continuing Operations (2016 - 2026)

Corvus Pharmaceuticals' Income from Continuing Operations history spans 12 years, with the latest figure at 13093000.0 for Q1 2026.

  • Quarterly Income from Continuing Operations fell 183.23% to 13093000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 42150000.0 through Mar 2026, down 12.62% year-over-year, with the annual reading at 13325000.0 for FY2025, 77.45% up from the prior year.
  • Income from Continuing Operations came in at 13093000.0 for Q1 2026, down from 11614000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 15732000.0 in Q1 2025 to a low of 39535000.0 in Q3 2024.
  • The 5-year median for Income from Continuing Operations is 7013000.0 (2022), against an average of 8224941.18.
  • Year-over-year, Income from Continuing Operations plummeted 669.91% in 2024 and then skyrocketed 364.98% in 2025.
  • Corvus Pharmaceuticals' Income from Continuing Operations stood at 5666000.0 in 2022, then grew by 7.36% to 5249000.0 in 2023, then plummeted by 89.35% to 9939000.0 in 2024, then fell by 16.85% to 11614000.0 in 2025, then decreased by 12.73% to 13093000.0 in 2026.
  • Per Business Quant, the three most recent readings for CRVS's Income from Continuing Operations are 13093000.0 (Q1 2026), 11614000.0 (Q4 2025), and 9834000.0 (Q3 2025).